ESR1 peptides vaccine study (Breast Cancer)

Purpose of this Study

We are doing this study to find out if a new vaccine (ESR1 peptides) is safe and if they will help people with estrogen receptor positive (ER+) breast cancer.

Who Can Participate?

Eligibility

Adults who:<ul>
<li>Are diagnosed with breast cancer
<li>Have completed chemotherapy or surgery

Age Range

18-100

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

If you choose to join this study you will:<ul>
<li>Get the study vaccine (ESR1 peptide)</li>
<li>Return to the Duke Cancer Center for follow-up visits 6-8 times over 10 weeks</li>
<li>Be contacted by phone every 12 weeks to see how you are doing</li>
<li>Have a skin biopsy (piece of skin will be taken) where the study vaccine was injected</li>

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Phase I Study of Cancer Peptides plus GM-CSF and Adjuvant Following Completion of Prescribed Systemic Therapy of Estrogen Receptor Positive Breast Cancer

Principal Investigator

Michael
Morse

Protocol Number

PRO00104868

NCT ID

NCT04270149

Phase

I

Enrollment Status

Open to Enrollment